Floatz logo

Siponimod

Cognitive Impairment, Mild

St. Joseph's Hospital and Medical Center, PhoenixSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

0 Active assets in the Cognitive Impairment, Mild cohort.

Asset / SponsorPhaseRating

Same molecule, other indications

Siponimod is also rated in:

secondary progressive multiple sclerosisDormant
BBB
Indicative ·
75 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BB
Indicative ·
64 / 100
View asset →
hemorrhagic strokeDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →